Physician profile
James Avery Rush
NPI 1376512400
$53,583.96
in general payments reported to CMS, 2019-2025
15 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $4,948 · 2021: $2,868 · 2022: $7,220 · 2023: $362 · 2024: $379 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $1,876 · Food and Beverage: $1,675 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,650.00 |
| Travel and Lodging | $1,875.66 |
| Food and Beverage | $1,675.01 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,272.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $8,316.94 | 2019-2025 | Spravato |
| Rxsight INC | $5,891.23 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Teva Pharmaceuticals USA, INC. | $561.37 | 2019-2024 | Austedo, Austedo Xr |
| Alcon Vision LLC | $525.36 | 2019-2024 | Clareon |
| Acadia Pharmaceuticals INC | $299.45 | 2019-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $211.24 | 2020-2023 | Trintellix |
| Lundbeck LLC | $117.88 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $98.15 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $90.59 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $88.20 | 2022-2025 | |
| Glaukos Corporation | $61.37 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.65 | 2019 | |
| Alfasigma USA, INC. | $16.64 | 2020 | |
| Tris Pharma INC | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.